MitraClip® Benefits People with Mitral Regurgitation

Favorable one-year outcomes are being touted by Abbott from the largest study of real-world experience for the MitraClip system in transcatheter mitral valve repair (TMVR) procedures in the United States.


Mitral regurgitation is a debilitating, progressive and life-threatening disease in which the leaflets of the mitral valve do not close completely, causing blood to flow backward and leak into the left atrium of the heart during the cardiac cycle. The condition can raise the risk of irregular heartbeats, stroke, and heart failure, which can be deadly.

MitraClip treats people with degenerative mitral regurgitation (DMR, also known as leaky heart valve), a serious condition involving a dysfunction of the heart’s mitral valve, which regulates blood flow into the heart’s main pumping chamber.

The study analyzed data from the Transcatheter Valve Therapy (TVT) registry involving nearly 3,000 DMR patients who were high-risk for surgery. Following minimally invasive implantation with MitraClip, patients had significant improvements, including 92.8 percent of patients achieving post-procedural mitral regurgitation (MR) severity grade of less than or equal to 2 (acute procedural success defined as MR =2). In addition, 80.0 percent of MitraClip patients remained free from heart failure (HF) re-hospitalization in the year after implantation. Most patients–85.9 percent of people treated–were discharged to their homes after an average hospital stay of only two days. The average age of patients was 82.

The data were presented by Paul Sorajja, M.D., director of the Center of Valve and Structural Heart Disease at Minneapolis Heart Institute, cardiologist at Abbott Northwestern Hospital in Minneapolis and principal investigator of the study, during a late-breaking featured clinical research session of the American College of Cardiology’s (ACC) 66th Annual Scientific Session.

Investigator comments

“The consistent one-year results seen in this study validate that treatment with MitraClip can provide meaningful reduction in the severity of mitral regurgitation,” said Dr. Sorajja. “The consistency of data over time in this large patient registry underscore the valuable impact MitraClip has on the overall health of very sick people living with this silent killer.”

Company comments

“Abbott’s goal is to improve health, and our MitraClip therapy provides a much-needed solution for gravely ill people who have very few options,” said Michael Dale, general manager of Abbott’s structural heart business. “The consistency in data across multiple trials reinforce the nearly immediate impact that MitraClip has on people’s quality of life, allowing them to lead fuller, longer lives.”

Source: Abbott

Share your thoughts

Your email address will not be published. Required fields are marked *